Table 1.

Patient characteristics.

	Age	Sex	Time from Diagnosis	Localization	WHO Grade	Treatment	Ki 67 Index Primitive	Ki 67 Index Recurrence	Neurological Deficit	ECOG PS
1	74	F	3 years	Multiple meningioma, metastasis	II	Surgery, EBRT, SRS, Sandostatine-Everolimus	15–20%	N/A	motor deficit, confusion	2
2	85	F	17 years	multiple meningioma; subcutaneous frontal lesion	II	Surgeryx3, SRSx2, EBRT	15%	N/A	visual disturbance	2
3	67	M	9 years	multiple meningioma	II	Surgeryx2, EBRT, SRS, Sandostatine-Everolimus	N/A	2%	left hemiparesis	2
4	72	M	19 years	multiple meningioma	II	Surgeryx2, EBRT, SRS, Sandostatine-Everolimus	N/A	25%	visual disturbance; frontal syndrome	1
5	60	M	9 years	multiple meningioma, metastasis	III; II	Surgeryx2, parotidectomy, EBRT	30–40%	10%	asthenia, attention deficit disorder	1
6	76	M	15 years	multiple meningioma	II	Surgeryx5, EBRT, SRSx3	10–15%	25; 20%	none	0
7	73	F	15 years	multiple meningioma	II	Surgeryx2, EBRT, SRS	10%	N/A	visual disturbance, ptosis, trigeminal neuralgia	1
8	67	M	11 years	multiple meningioma	II	Surgery, EBRT	N/A	N/A	left upper limb deficiency,	1

N/A: not available.3.2. Response Assessment MRI.